Scholarlink

Purpose <p>To analyze prognostic factors and survival outcomes in patients with synchronous endometrial and ovarian cancer (SEOC) to guide clinical management.</p> Methods <p>We conducted a retrospective cohort study of patients diagnosed with SEOC at Peking University People’s Hospital between January 2004 and December 2024. Clinicopathological data were collected, and oncological outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed along with their associated prognostic factors.</p> Results <p>Among 64 included patients, vaginal bleeding was the predominant presenting symptom. Thirty-six patients were diagnosed with concordant endometrioid carcinoma, which was the most common histological type. All patients underwent surgical treatment, among whom 56 received platinum-based chemotherapy postoperatively, with a platinum sensitivity rate of 67.9%. The median PFS and OS were 27&#xa0;months (range 3–215) and 41&#xa0;months (range 7–246), respectively. On multivariate analysis, advanced FIGO stage of ovarian cancer (HR = 2.764; 95% CI 1.169–6.536, <i>P</i> = 0.021) independently predicted worse PFS, while platinum resistance (HR = 6.962; 95% CI 2.052–23.619,<i> P</i> = 0.002) was significantly associated with reduced OS.</p> Conclusions <p>In this cohort, platinum sensitivity was observed in 67.9% of cases. The advanced ovarian FIGO stage and platinum resistance independently correlated with inferior survival, underscoring the urgent need for tailored therapeutic strategies and intensified surveillance in platinum-resistant SEOC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes and prognostic factors in patients with synchronous endometrial and ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月4日

查看全文
  • Xiaofei Lu,
  • Honglan Zhu

摘要

Purpose

To analyze prognostic factors and survival outcomes in patients with synchronous endometrial and ovarian cancer (SEOC) to guide clinical management.

Methods

We conducted a retrospective cohort study of patients diagnosed with SEOC at Peking University People’s Hospital between January 2004 and December 2024. Clinicopathological data were collected, and oncological outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed along with their associated prognostic factors.

Results

Among 64 included patients, vaginal bleeding was the predominant presenting symptom. Thirty-six patients were diagnosed with concordant endometrioid carcinoma, which was the most common histological type. All patients underwent surgical treatment, among whom 56 received platinum-based chemotherapy postoperatively, with a platinum sensitivity rate of 67.9%. The median PFS and OS were 27 months (range 3–215) and 41 months (range 7–246), respectively. On multivariate analysis, advanced FIGO stage of ovarian cancer (HR = 2.764; 95% CI 1.169–6.536, P = 0.021) independently predicted worse PFS, while platinum resistance (HR = 6.962; 95% CI 2.052–23.619, P = 0.002) was significantly associated with reduced OS.

Conclusions

In this cohort, platinum sensitivity was observed in 67.9% of cases. The advanced ovarian FIGO stage and platinum resistance independently correlated with inferior survival, underscoring the urgent need for tailored therapeutic strategies and intensified surveillance in platinum-resistant SEOC.